{
  "id": 2407974,
  "title": "CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?",
  "url": "https://urgent.news/2026/08/21/crispr-therapeutics-stock-is-up-only-8-this-year-is-cathie-woods-bet-2407974",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-21T14:30:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/08/21/crispr-therapeutics-stock-is-up-only-8-this-year/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "CRISPR Therapeutics, a biotech company focused on gene-editing technology, has seen a modest rise in its stock price this year, increasing by over 8%, which is far below the Nasdaq Biotechnology index's 27% return and slightly under the 12% performance of the S&P 500. This lackluster growth may raise questions about the current investment bet by Cathie Wood, renowned for her success in the biotech sector, through her Ark Invest ETFs. Wood holds a significant stake in CRISPR Therapeutics, owning 94.6 million shares with an average price of $66. However, with the current stock price hovering around $52, she has unfortunately taken a loss on her investment.\n\nDespite the present-day challenges, Wood remains optimistic about the biotech company's long-term potential. CRISPR Therapeutics, named after its groundbreaking CRISPR gene-editing technology, offers a compelling long-term investment opportunity. Its lead therapy, Casgevy, which is used to treat rare blood disorders like sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TBT), has demonstrated impressive revenue growth. Additionally, the company is set to enter a phase 3 trial for its promising candidate CTX611, and it possesses nine other therapies in its pipeline, which could generate future revenue streams.",
  "summary": "This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?",
        "url": "https://urgent.news/2026/08/21/crispr-therapeutics-stock-is-up-only-8-this-year-is-cathie-woods-bet",
        "published": "2026-08-21T14:50:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}